Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO
Catheter Precision, Inc. (NYSE American:VTAK) has announced the completion of patient follow-up for the VIVO European Registry, which enrolled 125 patients from October 2021 to June 2023. The registry aims to collect real-world data on VIVO's use and benefits for pre-procedure planning of ventricular ablation. Data is expected to be available in Q4 2024.
Additionally, the company reported new product evaluations of VIVO. Three European hospitals, including Manchester University NHS, Wythenshawe Hospital (UK), Institute for Clinical and Experimental Medicine (Prague), and Cardinal Massaia Hospital (Italy), are beginning evaluations in July. Two US hospitals in California and Washington are also scheduled to start VIVO procedures this month as part of initial evaluations.
- Completion of patient follow-up for VIVO European Registry with 125 patients enrolled
- Ongoing studies for VIVO and LockeT product lines
- New product evaluations of VIVO in three European hospitals
- Two new US hospitals scheduled to begin VIVO procedures
- None.
Insights
Catheter Precision's VIVO European Registry, which began in October 2021, has completed its patient follow-up phase. Enrolling 125 patients, the registry aims to collect real-world data on VIVO, a device used in pre-procedure planning of ventricular ablation. This data will not only comply with European regulatory requirements but also aid in future studies and improvements in the VIVO technology.
Given the nature of these announcements, there are some key insights to consider:
- Regulatory Compliance: Completion of the patient follow-up phase is important for regulatory compliance in Europe. Meeting these requirements will ensure that VIVO remains a viable option for ventricular ablation procedures in the European market. This is important as compliance with regulatory standards enhances the trust and credibility of the device and the company, potentially increasing market acceptance and usage.
- Data Availability: The expected release of data in Q4 2024 will be a pivotal moment. Investors should watch for this data as it will provide concrete evidence on the efficacy and benefits of VIVO, influencing future sales and market penetration. Positive results could serve as a catalyst for stock growth.
Overall, the completion of this phase represents a significant milestone for Catheter Precision. It not only reinforces their commitment to evidence-based practice but also strengthens their position in the European market.
The announcement that three new European hospitals and two US hospitals are beginning initial evaluations of the VIVO device is notable. This development suggests a growing interest and potential market expansion for Catheter Precision's products. Here are some takeaways:
- Market Penetration: The initiation of VIVO evaluations in new hospitals is a strategic move to increase adoption. Successful evaluations could lead to broader use of the VIVO device, positively impacting revenue streams and market share.
- Geographic Expansion: Expanding evaluations to both European and US hospitals highlights Catheter Precision's efforts to diversify its market presence. This geographic spread could buffer the company against regional market fluctuations and regulatory challenges.
- Future Sales: If the VIVO device meets the expectations of these new hospitals, it could result in long-term contracts and recurring revenue from these institutions. This is a positive indicator of future sales growth and market stability.
From an investor's perspective, these hospital evaluations serve as preliminary steps towards potentially higher adoption rates and increased sales, which could positively influence the company's financial performance and stock value.
FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.
As previously disclosed, the EU registry enrolled 125 patients with an aim to gather real world data about the use and benefits of VIVO, outside of a rigorous clinical study. The data serves multiple purposes including fulfilling European regulatory requirements for on-going data collection, publication of multi-center data, and future development of studies and improvements to the VIVO technology, including a demonstration of the accuracy and benefits of VIVO for pre-procedure planning of ventricular ablation. The data is expected to become available in Q4 2024. In addition to the conclusion of the EU Registry, Catheter Precision continues the ongoing studies it has previously disclosed as part of its commitment to gathering and publishing clinical data for the company's two product lines, VIVO and LockeT.
The Company also announced additional initial evaluations of VIVO. During July, three new European hospitals are beginning product evaluations including Manchester University NHS, Wythenshawe Hospital (UK), Institute for Clinical and Experimental Medicine (Prague), and Cardinal Massaia Hospital (Italy). In addition, two new US hospitals in California and Washington have been in-serviced and are scheduled to begin VIVO procedures this month as part of such initial evaluations.
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About LockeT
Catheter Precision's LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "ongoing," "predict," "plan," "rely," "should," "will," "may," "seek," "would," "forward," or the negative and alternative word forms of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding company plans for the availability and publication of data from the EU Registry in Q4 2024, as well as its continuing pursuit of other studies and the gathering and publishing of additional clinical data for the company's two product lines, VIVO and Locket. Such statements also include any implied statements regarding the potential benefits to flow from the EU Registry and the Company's other ongoing and future studies, as well as any implied statement about the continued successful build out of VIVO. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to the risk that members of the EP community and other doctors and hospitals will fail to recognize VIVO's value or for other reasons will prefer other methodologies and/or products, including the products of our current competitors as well as possible new and emerging competing products of which we are not yet aware; the risk that customers and new hospitals may not make additional purchases in the future and that hospitals undergoing initial evaluations may not choose to continue using VIVO following such evaluation; risks that we will be unable to obtain the necessary financing to carry out our business goals, including to continue ongoing efforts to gather and publish clinical data and to build out VIVO; risk that peer-reviewed journals or other journals may choose not to publish data submitted in connection with our products; risks that our business relationships with distribution partners and customers could be disrupted by armed conflicts and unrest in Israel and the Gaza strip and elsewhere, and/or changes in U.S. international relations and/or related geopolitical changes; and other, or disruptions to local and global economies; and the other risks and uncertainties attendant to our business included under the caption "Risk Factors" in the Company's Form 10-K and other SEC filings available at www.sec.gov. These additional risks and uncertainties include, but aren't limited to, risks that our cash needs will continue to exceed our liquidity, we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of December 31, 2023 and March 31, 2024, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components and finished product in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components or finished product, or we may be unable to manage these components or product procurement effectively or obtain these components or products on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to potential product liability risks as well as additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, disruptions to our ability to conduct business overseas, including to our supply chain, from the Ukraine war, the Israeli-Hamas armed conflict and other ongoing hostilities and instabilities in the Middle East and elsewhere, and ongoing volatility in the stock markets and the U.S. economy in general. In addition, market conditions that are outside our control could significantly how our stock is viewed by potential investors.
CONTACTS:
At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com
SOURCE: Catheter Precision, Inc
View the original press release on accesswire.com
FAQ
When will the data from the VIVO European Registry be available for Catheter Precision (VTAK)?
How many patients were enrolled in Catheter Precision's (VTAK) VIVO European Registry?
Which European hospitals are beginning product evaluations of VIVO in July 2024?
When did the patient enrollment for Catheter Precision's (VTAK) VIVO European Registry conclude?
